Company
Cognigenics
RNAi delivered directly to the brain.
Also known as Cognigenics, Inc
- Status
- Operatingas of 2026-09-20
- Business model
- B2B
- Legal name
- Cognigenics, Inc
Claim, correct or request removal
Record updated 29 September 2026
About
Cognigenics is developing iRNAi™, a precise, non-invasive, intranasal RNA interference platform that delivers programmable therapeutics directly to key areas of the brain to modulate the neural circuits underlying mood, memory, and cognition—supporting lasting brain health and cognitive function across the lifespan.
Funding snapshot
- Total raised
- $1.6MSEC form D sum, as of 2026-09-29Source (opens in a new tab)
- Latest round
- Round, $1.6M2022-06-13
Funding rounds
- Round, 2022
- $1.6M2022-06-13, SEC form D sold, 3 investors
Products
- Other
- iRNAi™
Loading relationship preview